Themis Medicare Share Price

NSE
THEMISMED •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Themis Medicare Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
46.00% Gain from 52W Low
-7.7
TTM PE Ratio
Below industry Median
45.8
Price to Book Ratio
Above industry Median
6.4
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is much higher than 1
13.3

Themis Medicare Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Themis Medicare Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
117.01 Cr
122.99 Cr
97.82 Cr
82.51 Cr
104.78 Cr

Themis Medicare Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
386.52 Cr
365.83 Cr
401.16 Cr
234.29 Cr
205.05 Cr

Themis Medicare Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
9.87 Cr
18.71 Cr
3.07 Cr
2 Cr
7.1 Cr

Themis Medicare Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
24.72 Cr
43.28 Cr
61.54 Cr
26.23 Cr
15.88 Cr

Themis Medicare Ltd shareholding Pattern

Promoter
67.2%
Foreign Institutions
0.1%
Public
32.7%
Promoter
67.2%
Domestic Institutions
0.1%
Public
32.8%
Promoter
67.2%
Public
32.8%
Promoter
67.2%
Public
32.8%
Promoter
67.2%
Domestic Institutions
0.1%
Public
32.8%
Promoter
67.2%
Public
32.8%

Themis Medicare Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
3
Bearish Moving Averages
13
5Day EMA
274.50
10Day EMA
279.40
12Day EMA
280.50
20Day EMA
282.10
26Day EMA
282.00
50Day EMA
278.20
100Day EMA
267.30
200Day EMA
247.40
5Day SMA
275.00
10Day SMA
282.50
20Day SMA
287.00
30Day SMA
284.40
50Day SMA
278.00
100Day SMA
268.70
150Day SMA
251.80
200Day SMA
243.90
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
216833 Rs
447007 Rs
Week Rs
105452 Rs
198865 Rs
Month Rs
139966 Rs
260221 Rs
Resistance & Support
269.17
Pivot
Resistance
First Resistance
275.33
Second Resistance
282.02
Third Resistance
288.18
Support
First Support
262.48
Second support
256.32
Third Support
249.63
Relative Strength Index
37.68
Money Flow Index
13.55
MACD
-1.46
MACD Signal
1.77
Average True Range
11.12
Average Directional Index
17.14
Rate of Change (21)
-6.62
Rate of Change (125)
22.31

Themis Medicare Ltd Company background

Founded in: 1969
Managing director: Sachin D Patel
Themis Medicare Limited was formerly incorporated as Themis Chemicals Limited in 1969. The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993. Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.In Mar.95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansioncummodernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment longterm working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of antituberculosis, cerebroactivators, bronchodilators, antiasthmatic, anaesthetic and other segments.Antituberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an antibacterial drug, for veterinary use for which it has a confirmed buyback arrangement with Chinoin, Hungary.The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its AntiT.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.The Company introduced products like Cardiac and Muscular Relaxant during the year 200102. A wholly owned subsidiary of the Company, Themis Medicare Singapore Pte. Ltd., formed on 22nd May, 2002 in Singapore became operational during the year 200203. M/s. Artemis Biotech Ltd., a Group Company was merged with Themis Medicare Ltd. (the Parent Company) with effect from 1st April 2003. The Joint Venture Company, Richter Themis Medicare (India) Pvt. Ltd. started manufacturing activities at its EOU unit at Vapi effective from March, 2006. The Company started operations of its new Injection Plant at Haridwar for tablets and gel formulation production in 200607. Themiseal, the Companys unique haemostatic and antimicrobial product was launched in the UK, Greece, Cyprus, Jordan, Romania and Indonesia.During the year 201011, a Private Ltd Subsidiary Company in the name and style of Themis Lifestyle Pvt. Ltd was incorporated on 3rd November, 2010 and another Public Ltd Subsidiary Company in the name and style of Artemis Biotech Ltd. was incorporated on 14th January, 2011.During FY 201617, HIDPUL KFT (Hungary), a Wholly Owned Subsidiary of the Company, ceased to be a subsidiary of the Company. Carpo Medical Limited was incorporated as a Joint Venture Company in the United Kingdom in 201617.The Company launched a new product Lenzetto Global brand of Estradiol Novel Drug Delivery System for treatment of Menopausal symptoms in 2023. As part of a strategy to concentrate on both the API and the Hospital Business, the Company demerged the API segment of the Company, including both the API production facilities, to a 100% owned subsidiary company, Themis Lifestyle Private Limited through slump sale in 2023.
Read More

Themis Medicare Ltd FAQs

Themis Medicare Ltd shares are currently priced at 264 on NSE and 264.65 on BSE as of 12/20/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Themis Medicare Ltd [THEMISMED] share was 44.61. The Themis Medicare Ltd [THEMISMED] share hit a 1-year low of Rs. 168.55 and a 1-year high of Rs. 317.

The market cap of Themis Medicare Ltd is Rs. 2472.66 Cr. as of 12/20/2024 12:00:00 AM.

The PE ratios of Themis Medicare Ltd is 65.65 as of 12/20/2024 12:00:00 AM.

The PB ratios of Themis Medicare Ltd is 8.46 as of 12/20/2024 12:00:00 AM

You can easily buy Themis Medicare Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -